FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Novartis | Generics | Eli Lilly | Patent

Lilly beset by potential Strattera imitators

Tools

Strattera poachers are besieging Eli Lilly on all sides. Sandoz, the Novartis generics unit, is challenging Lilly's patent on the hyperactivity drug, set to expire in 2017, in federal court. Sandoz is seeking a pre-emptive ruling to protect its copycat version of Strattera. This comes after Lilly filed suit against Iceland-based Actavis Group to block that company's Strattera generic. And no wonder Lilly's so protective: the drug generated $282 million for the company during the first half of 2007.

- here's the report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Novartis   Generics   Eli Lilly   Patent  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.